Amparo Larrauri

Dr. Amparo Larrauri

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet
Verified
Journal Article
Closed access
AIA Danielle Iuliano
A Danielle Iuliano
KRKatherine M Roguski
Katherine M Roguski
HCHoward H Chang
Howard H Chang
DMDavid J Muscatello
David J Muscatello
RPRakhee Palekar
Rakhee Palekar
DMDesiree Mustaquim
Desiree Mustaquim

1 July 2005 in Vaccine
Verified
Journal Article
Closed access
ALAmparo Larrauri
Amparo Larrauri
RCRosa Cano
Rosa Cano
MGMartina García
Martina García
SMSalvador de Mateo
Salvador de Mateo

30 May 2015 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
TVTomás Vega
Tomás Vega
JLJosé E. Lozano
José E. Lozano
TMTamara Meerhoff
Tamara Meerhoff
RSRené Snacken
René Snacken
JBJulien Beauté
Julien Beauté
CBCaroline Brown
Caroline Brown
Objectives: Although influenza‐like illnesses (ILI) and acute respiratory illnesses (ARI) surveillance are well established in Europe, the comparability of intensity among countries and seasons remains an unresolved challenge. The objective is to compare the intensity of ILI and ARI in some European countries.Design and setting: Weekly ILI and ARI incidence rates and proportion of primary care consultations were modeled in 28 countries for the 1996/1997–2013/2014 seasons using the moving epidemic method (MEM). We calculated the epidemic threshold and three intensity thresholds, which delimit five intensity levels: baseline, low, medium, high, and very high. The intensity of 2013/2014 season is described and compared by country.Results: The lowest ILI epidemic thresholds appeared in Sweden and Estonia (below 10 cases per 100 000) and the highest in Belgium, Denmark, Hungary, Poland, Serbia, and Slovakia (above 100 per 100 000). The 2009/2010 season was the most intense, with 35% of the countries showing high or very high intensity levels. The European epidemic period in season 2013/2014 started in January 2014 in Spain, Poland, and Greece. The intensity was between low and medium and only Greece reached the high intensity level, in weeks 7 to 9/2014. Some countries remained at the baseline level throughout the entire surveillance period.Conclusions: Epidemic and intensity thresholds varied by country. Influenza‐like illnesses and ARI levels normalized by MEM in 2013/2014 showed that the intensity of the season in Europe was between low and medium in most of the countries. Comparing intensity among seasons or countries is essential for understanding patterns in seasonal epidemics. An automated standardized model for comparison should be implemented at national and international levels.

1 January 2007 in FEMS Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
CTCaroline Trotter
Caroline Trotter
MCManosree Chandra
Manosree Chandra
RCRosa Cano
Rosa Cano
ALAmparo Larrauri
Amparo Larrauri
MRMary E. Ramsay
Mary E. Ramsay
MFMatthias Frosch
Matthias Frosch

11 January 2011 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MVMarta Valenciano
Marta Valenciano
EKEsther Kissling
Esther Kissling
JCJean-Marie Cohen
Jean-Marie Cohen
BOBeatrix Oroszi
Beatrix Oroszi
ABAnne-Sophie Barret
Anne-Sophie Barret
AMAlain Moren
Alain Moren
A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009–2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1). Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6–85.5) overall; 78.4% (95% CI 54.4–89.8) in patients <65 years; and 72.9% (95% CI 39.8–87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9–84.8), 71.3% (95% CI 29.1–88.4), and 70.2% (95% CI 19.4–89.0), respectively. The adjusted PIVE was 66.0% (95% CI −69.9 to 93.2) if vaccinated 8–14 days before ILI onset. The adjusted 2009–2010 seasonal influenza VE was 9.9% (95% CI −65.2 to 50.9). Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009–2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010–2011 season, when vaccination will occur before the influenza season starts. Please see later in the article for the Editors' Summary

1 October 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
JNJ. Nielsen
J. Nielsen
LVL.S. Vestergaard
L.S. Vestergaard
LRL. Richter
L. Richter
DSD. Schmid
D. Schmid
NBN. Bustos
N. Bustos
TKT.G. Krause
T.G. Krause
Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high excess mortality during the influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe all-cause excess and influenza-attributable mortality during the season 2017/18 in Europe. Based on weekly reporting of mortality from 24 European countries or sub-national regions, representing 60% of the European population excluding the Russian and Turkish parts of Europe, we estimated age stratified all-cause excess morality using the EuroMOMO model. In addition, age stratified all-cause influenza-attributable mortality was estimated using the FluMOMO algorithm, incorporating influenza activity based on clinical and virological surveillance data, and adjusting for extreme temperatures. Excess mortality was mainly attributable to influenza activity from December 2017 to April 2018, but also due to exceptionally low temperatures in February-March 2018. The pattern and extent of mortality excess was similar to the previous A(H3N2) dominated seasons, 2014/15 and 2016/17. The 2017/18 overall all-cause influenza-attributable mortality was estimated to be 25.4 (95%CI 25.0-25.8) per 100,000 population; 118.2 (116.4-119.9) for persons aged 65. Extending to the European population this translates into over-all 152,000 deaths. The high mortality among elderly was unexpected in an influenza B dominated season, which commonly are considered to cause mild illness, mainly among children. Even though A(H3N2) also circulated in the 2017/18 season and may have contributed to the excess mortality among the elderly, the common perception of influenza B only having a modest impact on excess mortality in the older population may need to be reconsidered.